iHealthScreen Secures US Patent for AI-Based Glaucoma Detection Tool

iHealthScreen has been granted a full US patent for its iPredict glaucoma detection model by the US Patent and Trademark Office (USPTO) as of March 26, 2024. This advanced model leverages AI and color fundus imaging to provide swift and reliable detection of glaucoma, making it a valuable tool in primary care settings for the early screening of the disease.

Innovative Detection Technology

The iPredict system utilizes high-resolution images from a color fundus camera to generate a fully automated glaucoma detection report in under 60 seconds. The comprehensive process, including image capture and report generation, takes approximately five minutes and boasts a remarkable accuracy rate of 94.3% in identifying individuals with glaucoma.

iHealthScreen's technology not only distinguishes between referable stages of glaucoma (early to severe) and non-referable cases (not glaucoma) but also advises on subsequent steps. Patients identified with referable glaucoma are recommended for further evaluation by a specialist.

Regulatory Approvals and Further Applications

Additionally, iHealthScreen's portfolio includes AI-driven screening tools for diabetic retinopathy and age-related macular degeneration (AMD), all of which have received international regulatory approvals. These tools recommend follow-up actions based on the detected condition, ranging from immediate specialist referral to standard annual screenings.

iPredict is designed for use in various healthcare settings, enabling providers to efficiently identify potential cases of diabetic retinopathy, AMD, and glaucoma, thus facilitating early intervention and better patient care outcomes.